Sanofi

Sanofi-Aventis

Elf Sanofi

Sanofi Sa

Alain Badorc

Daniel Frehel

Marie-Francoise Bordes

Jean-Marc Herbert

Francoise Bono

Jean-Pierre Maffrand

Nathalie Guillo

Chantal Alcouffe

Paul De Cointet

Pierre Despeyroux

Daniele Anne Gully

Robert Boigegrain

Danielle Gully

Gilbert Lassalle

Claudine Serradeil-Legal

Jean-Michel Foidart

Valérie Fossey

Pierre Savi

Antonina Giudice

Eric Vallee

Gernot Zech

Jean-Pierre Bras

Agnes Noel

Jean-Marie Rakic

Andr E Bernat

Denis Delebass Ee

Marie-Francedillaoise Bordes

Xavier Yvon

Gilles Kieffer

Ghislain Defreyn

Jean Courregelongue

Daniel Ducros

Christophe Boldron

Nathalie Delesque

Angelina Besse

Marie-Françoise Bordes

The invention concerns compounds of formula I, a method for preparing said compounds, pharmaceutical compositions containing same and the therapeutic uses thereof. 

Imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same

The present invention relates to compounds corresponding to formula (I): 

[object Object]

The present invention thus relates to the use of 1,2,3-substituted indolizine derivatives in the preparation of medicaments of use in the treatment of diseases related to pathological choroidal angiogenesis, which derivatives correspond to the following general formula (I): 

Use of FGF inhibiting substituted 1,2,3 indolizine derivatives in the preparation of medicaments which can be used to treat diseases linked to pathological choroidal angiogenesis

Imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same

The present invention relates to novel 1,2,3-substituted indolizine derivative which are inhibitors of fibroblast growth factors, to methods or preparing such derivatives, to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising such derivatives.

1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them

The invention is directed to a compound of formula I, wherein R, R, R, Rand Rare as defined herein, or a pharmaceutically acceptable salt thereof, and its pharmaceutically composition, preparation and uses as an inhibitor of FGFs (fibroblast growth factors).

Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives

Compounds of formula I or salts thereof: in which

1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same

The invention relates to the compounds of formula (I) ##STR1## in which R.sub.I, R.sub.II, X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are as defined in claim 1.

Polysubstituted 3-acylamino-5-phenyl-1,4-benzodiazepin-2-one

Polysubstituted 3-acylamino-5-phenyl-1, 4-benzodiazepin-2-one

The invention concerns compounds of formula ##STR1## in which R, A, R.sub.1 and Y are as defined in claim 1. The instant compounds have an affinity for the fibrinogen receptor: the complex of the glycoproteins IIb/llIa (GP IIb/IIIa); more particularly, the subject of the present invention is new inhibitors of platelet aggregation which are antagonists of the GP IIb/IIIa receptors, of nonpeptide structure, which are active via the parenteral and oral routes.

Substituted 4-phenylthiazole derivatives, process for their preparation

The invention relates to a new method for the secondary prevention of ischemic events comprising administering to a man in need thereof a therapeutically effective amount of a compound selected from clopidogrel and its pharmaceutically acceptable acid addition salts in association with a pharmaceutically acceptable carrier.

Method for the secondary prevention of ischemic events

The invention relates to thiadiazole derivatives corresponding to the general formula ##STR1## in which Ar represents a nitrogen-containing aromatic heterocycle, in particular indolyl which is substituted or unsubstituted on the nitrogen atom with CO--(C.sub.1 -C.sub.4)alkyl; with (CH.sub.2).sub.n COR in which n represents 1 or 2 and R represents OR.sub.1 or NR.sub.1 R.sub.2 with R.sub.1 and R.sub.2, which may be identical or different, representing H or (C.sub.1 -C.sub.4)alkyl; with (C.sub.1 -C.sub.4) hydroxyalkyl; with (C.sub.2 -C.sub.6) alkoxyalkyl; tetrahydropyranyl; or with a --(CH.sub.2).sub.3 -- chain, the last carbon of which is attached to the phenyl ring of the indole to form a 6-membered ring;

5-acylamino-1,2,4-thiadiazoles, their preparation and pharmaceutical

The compounds of the invention having the formula: ##STR1## in which: A, which is a ring condensed with cyclopentane, represents a substituted or unsubstituted thiophene ring, Q represents an alkylene chain, R.sub.1 and R.sub.2 each represent H or an alkyl, or they form, with the nitrogen atom to which they are linked, a saturated nitrogenous heterocyclic ring containing 5 to 7 atoms, R.sub.3 and R.sub.4 each represent H, alkyl, cycloalkyl, trifluoromethyl or an optionally substituted phenyl, thienyl or furyl group or R.sub.3 and R.sub.4 together form a (C.sub.5 -C.sub.8) cycloalkyl, as well as their addition salts with an acid and their quaternary ammonium derivatives. They can be used as medicines.

Ethers of thienocyclopentanone oximes, their preparation and

The invention relates to compounds of formula ##STR1## in which R.sub.1 is selected from the groups R.sub.3 and OR.sub.3, R is selected from H and a group CHR.sub.2 R', in which R.sub.2 is selected from H, alkyl, carboxy and carboxamido and R', is H, alkyl or phenyl, Z represents S or O; and m and n, which may be identical or different, equal 1 or 2, and their N-oxides, salts and quaternary ammonium derivatives. The invention also relates to the process for preparing these compounds, as well as to pharmaceutical compositions containing them.

Derivatives of 2-hydroxythiophene and -furan fused with a

The present invention relates to the dextro-rotatory enantiomer of Formula ##STR1## and its pharmaceutically acceptable salts with platelet aggregation inhibiting activity. The invention also relates to a process for the preparation of this compound starting from the racemate and the pharmaceutical compositions containing it.

Dextro-rotatory enantiomer of methyl alpha-5 (4,5,6,7-tetrahydro (3,2-c)

Growing community of inventors

Roquettes, France

Alain Badorc